Press release archive | Oxurion — Advancing Science. Enhancing Vision

EN
NL

Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Press release archive

Oxurion NV Business Update – Q3 2019
18 Oct 2019
Oxurion NV to Provide Business and Clinical Update at Upcoming American Academy of Ophthalmology annual meeting (AAO) and Ophthalmology Innovation Summit (OIS @AAO) in San Francisco
9 Oct 2019
Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME
9 Sep 2019
Oxurion NV Business Update – H1 2019
5 Sep 2019
Oxurion Completes Enrollment of Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for the Treatment of Diabetic Macular Edema (DME)
4 Sep 2019
Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019
2 Sep 2019
Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME
20 Aug 2019
Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME
1 Jul 2019
ONCURIOUS NV Receives Project Grant from VLAIO to Progress its Pipeline of Next Generation Cancer Immunotherapies
11 Jun 2019
Oxurion NV - Data from Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting
6 Jun 2019
Regulated information - Transparency Statement Clay
10 May 2019
Regulated information - Transparency Statement OXUR shares
10 May 2019
Oxurion NV Business Update – Q1 2019
8 May 2019
Oxurion NV to Present Further Preclinical Data at 2019 ARVO Meeting
26 Apr 2019
Oxurion NV announces full enrollment in Phase 1 trial evaluating the safety of plasma kallikrein inhibitor THR-149 for treatment of DME, ahead of schedule
24 Apr 2019
Oxurion NV announces full enrollment of its Phase 2 trial evaluating efficacy and safety of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for the treatment of DME, ahead of schedule
4 Apr 2019
Oxurion NV Business Update – FY 2018
7 Mar 2019
Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting
28 Feb 2019
Oxurion NV to Present at the 2019 BIO CEO & Investor Conference
4 Feb 2019
Oxurion NV to Present at 2019 Biotech Showcase Conference and Participate in CEO Power Breakfast Roundtable during the 37th Annual J.P. Morgan Healthcare Conference
19 Dec 2018
Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMD
5 Nov 2018
Oxurion supports sight-saving diabetes programs
2 Nov 2018
Oxurion NV Announces the Appointment of Adrienne Graves to its Board of Directors
29 Oct 2018
Oxurion NV to Present at the Upcoming Ophthalmology Innovation Summit and Provide a Clinical Update at the American Academy of Ophthalmology 2018 Annual Meeting
24 Oct 2018
Oxurion NV Extends Partnership with Retina Global in Support of Bolivian Diabetic Retinopathy (BOLDR) Project
22 Oct 2018
Oxurion NV Business Update – Q3 2018
19 Oct 2018
Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1)
20 Sep 2018
Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME)
20 Sep 2018
Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 and THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria
17 Sep 2018
Oxurion NV Announces New Euronext Brussels Stock Ticker “OXUR” and Launch of New Website
10 Sep 2018
ThromboGenics Business Update – H1 2018
6 Sep 2018
ThromboGenics becomes "Oxurion"
3 Sep 2018
Regulated Information - Transparency Statement
27 Jul 2018
ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME)
19 Jul 2018
ThromboGenics Plans Name Change to “Oxurion”
27 Jun 2018
ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC
21 Jun 2018
ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)
25 May 2018
ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018
23 May 2018
ThromboGenics Presenting Industry Expertise and Developments at Bio€quity Europe and Knowledge for Growth meetings in Ghent, Belgium
14 May 2018
ThromboGenics Business Update – Q1 2018
9 May 2018

Pages